Functional Mapping of Neurodevelopmental Disease Pathways to Key Neurodevelopmental Processes Represented in the Developmental Neurotoxicity In Vitro Testing Battery. - 2026
Functional Mapping of Neurodevelopmental Disease Pathways to Key Neurodevelopmental Processes Represented in the Developmental Neurotoxicity In Vitro Testing Battery.
biological applicability domain; developmental neurotoxicity; neurosphere assay; new approach methodology; signaling pathways; Functional mapping; Neural progenitor cells; Neurospheres; New approaches; Oligodendrocytes; Signalling pathways; Medicine (miscellaneous); Chemical Engineering (all); Biochemistry, Genetics and Molecular Biology (miscellaneous); Materials Science (all); Engineering (all); Physics and Astronomy (all)
Abstract :
[en] The Developmental Neurotoxicity (DNT) in vitro battery (IVB) enables efficient and human-relevant evaluation of chemicals for DNT potential. To expand its biological applicability domain toward human disease, this study maps neurodevelopmental disorder (NDD)-relevant signaling pathways to key neurodevelopmental processes (KNDPs) using primary human fetal neural progenitor cells (NPCs). Using pharmacological intervention, eighteen NDD pathways are assessed for their impact on seven KNDPs, namely NPC proliferation, radial glia migration, neuronal and oligodendrocyte differentiation and migration, and neurite outgrowth. In total, modulation of sixteen pathways is associated with changes in at least one KNDP. Oligodendrocyte differentiation shows the highest sensitivity (13 pathways), followed by radial glia migration (11 pathways) and NPC proliferation (9 pathways), whereas neuronal migration remains unaffected. Perturbation of the RhoA and mitochondrial complex I pathways is associated with the broadest phenotypic responses, influencing five KNDPs each, while STAT3- and TrkB-related modulation falls outside the assay's applicability domain. Pathway-KNDP associations are integrated into an exemplary interactive physiological map of human oligodendrocyte development, linking mechanistic perturbations to human-relevant biology. Defining which NDD pathways can be functionally probed refines the DNT IVB's biological applicability domain, increases confidence in its protective power, and supports mechanistic interpretation of new approach methodology-based DNT assessment.
Disciplines :
Neurology Life sciences: Multidisciplinary, general & others
Author, co-author :
Kuchovska, Eliska ; IUF - Leibniz Research Institute for Environmental Medicine, Düsseldorf, Germany
Bartmann, Kristina ; IUF - Leibniz Research Institute for Environmental Medicine, Düsseldorf, Germany ; DNTOX GmbH, Düsseldorf, Germany
Raad, Georgea; IUF - Leibniz Research Institute for Environmental Medicine, Düsseldorf, Germany
Schade, Mats; IUF - Leibniz Research Institute for Environmental Medicine, Düsseldorf, Germany
Maia Ladeira, Luiz Carlos ; Université de Liège - ULiège > Département d'aérospatiale et mécanique > Génie biomécanique
Dönmez, Arif ; IUF - Leibniz Research Institute for Environmental Medicine, Düsseldorf, Germany ; DNTOX GmbH, Düsseldorf, Germany
Klose, Jördis; IUF - Leibniz Research Institute for Environmental Medicine, Düsseldorf, Germany ; DNTOX GmbH, Düsseldorf, Germany
Görts, Nicolai; IUF - Leibniz Research Institute for Environmental Medicine, Düsseldorf, Germany
Polozij, Denis; IUF - Leibniz Research Institute for Environmental Medicine, Düsseldorf, Germany
Saborowski, Lynn-Christin; IUF - Leibniz Research Institute for Environmental Medicine, Düsseldorf, Germany
Bendt, Farina; IUF - Leibniz Research Institute for Environmental Medicine, Düsseldorf, Germany ; DNTOX GmbH, Düsseldorf, Germany
Staumont, Bernard ; Université de Liège - ULiège > Département d'aérospatiale et mécanique > Génie biomécanique
Geris, Liesbet ; Université de Liège - ULiège > Département d'aérospatiale et mécanique > Génie biomécanique ; Skeletal Biology and Engineering Research Center, KU Leuven, Belgium ; Biomechanics Section, KU Leuven, Belgium
Koch, Katharina ; IUF - Leibniz Research Institute for Environmental Medicine, Düsseldorf, Germany ; DNTOX GmbH, Düsseldorf, Germany
Fritsche, Ellen ; IUF - Leibniz Research Institute for Environmental Medicine, Düsseldorf, Germany ; DNTOX GmbH, Düsseldorf, Germany ; SCAHT - Swiss Centre for Applied Human Toxicology & Department of Pharmaceutical Sciences, University of Basel, Switzerland
Functional Mapping of Neurodevelopmental Disease Pathways to Key Neurodevelopmental Processes Represented in the Developmental Neurotoxicity In Vitro Testing Battery.
OECD. Initial Recommendations on Evaluation of Data From the Developmental Neurotoxicity (DNT) In-Vitro Testing Battery; 2023. https://doi.org/10.1787/91964ef3-en.
E. Fritsche, P. Grandjean, K. M. Crofton, et al., “Consensus Statement on the Need for Innovation, Transition and Implementation of Developmental Neurotoxicity (DNT) Testing for Regulatory Purposes,” Toxicology and Applied Pharmacology 354 (2018): 3–6, https://doi.org/10.1016/j.taap.2018.02.004.
K. M. Crofton and W. R. Mundy, “External Scientific Report on the Interpretation of Data from the Developmental Neurotoxicity In Vitro Testing Assays for Use in Integrated Approaches for Testing and Assessment,” EFSA 18 (2021): 6924E, https://doi.org/10.2903/sp.efsa.2021.EN-6924.
M. Paparella, S. H. Bennekou, and A. Bal-Price, “An Analysis of the Limitations and Uncertainties of In Vivo Developmental Neurotoxicity Testing and Assessment to Identify the Potential for Alternative Approaches,” Reproductive Toxicology 96 (2020): 327–336, https://doi.org/10.1016/J.REPROTOX.2020.08.002.
L. Smirnova, H. T. Hogberg, M. Leist, and T. Hartung, “Food for Thought…: Developmental Neurotoxicity—Challenges in the 21st Century and In Vitro Opportunities,” Altex 31, no. 2 (2014): 129–156, 10.14573/altex.1403271.
L. Smirnova, H. T. Hogberg, M. Leist, and T. Hartung, “Revolutionizing Developmental Neurotoxicity Testing—A Journey from Animal Models to Advanced In Vitro Systems,” Altex 41, no. 2 (2024): 152–178, 10.14573/altex.2403281.
OECD. OECD Guidline for the testing of chemicals 443 Extended one-generation reproductive toxicity study 2025;(443): 1–25. http://scholar.google.com/scholar?hl=en&btnG=Search&q=intitle:Extended+One-Generation+Reproductive+Toxicity+Study#6%5Cnhttp://scholar.google.com/scholar?hl=en&btnG=Search&q=intitle:443:+Extended+One-Generation+Reproductive+Toxicity+Study%230.
U. Marx, T. Akabane, T. B. Andersson, et al., “Biology-Inspired Microphysiological Systems to Advance Patient Benefit and Animal Welfare in Drug Development,” Altex 37, no. 3 (2020): 365, 10.14573/ALTEX.2001241.
K. Gassmann, J. Abel, H. Bothe, et al., “Species-Specific Differential AhR Expression Protects Human Neural Progenitor Cells against Developmental Neurotoxicity of PAHs,” Environmental Health Perspectives 118, no. 11 (2010): 1571–1577, https://doi.org/10.1289/EHP.0901545.
K. Bozek, Y. Wei, Z. Yan, et al., “Organization and Evolution of Brain Lipidome Revealed by Large-Scale Analysis of Human, Chimpanzee, Macaque, and Mouse Tissues,” Neuron 85, no. 4 (2015): 695–702, https://doi.org/10.1016/j.neuron.2015.01.003.
X. Zhao and A. Bhattacharyya, “Human Models Are Needed for Studying Human Neurodevelopmental Disorders,” The American Journal of Human Genetics 103, no. 6 (2018): 829–857, https://doi.org/10.1016/J.AJHG.2018.10.009.
R. Nehme, O. Pietiläinen, and L. E. Barrett, “Genomic, Molecular, and Cellular Divergence of the human Brain,” Trends in Neuroscience (Tins) 47, no. 0 (2024): 491–505, https://doi.org/10.1016/j.tins.2024.05.009.
K. M. Crofton and W. R. Mundy, “Compendium of Information on the Use of Guideline-Based Developmental Neurotoxicity Studies*,” EFSA Supporting Publications 21, no. 12 (2024): 9174E, https://doi.org/10.2903/sp.efsa.2024.EN-9174.
M. Sachana, T. J. Shafer, and A. Terron, “Toward a Better Testing Paradigm for Developmental Neurotoxicity: OECD Efforts and Regulatory Considerations,” Biology (Basel) 10 (2021): 86, https://doi.org/10.3390/biology10020086.
S. Schmeisser, A. Miccoli, M. von Bergen, et al., “New Approach Methodologies in human Regulatory Toxicology—Not If, but How and When!,” Environment International 178 (2023): 108082, https://doi.org/10.1016/j.envint.2023.108082.
H. T. Hogberg and L. Smirnova, “The Future of 3D Brain Cultures in Developmental Neurotoxicity Testing,” Frontiers in Toxicology 4 (2022): 2, https://doi.org/10.3389/FTOX.2022.808620.
J. A. Harrill, T. Freudenrich, K. Wallace, K. Ball, T. J. Shafer, and W. R. Mundy, “Testing for Developmental Neurotoxicity Using a Battery of In Vitro Assays for Key Cellular Events in Neurodevelopment,” Toxicology and Applied Pharmacology 354 (2018): 24–39, https://doi.org/10.1016/J.TAAP.2018.04.001.
K. E. Carstens, A. F. Carpenter, M. M. Martin, J. A. Harrill, T. J. Shafer, and K. Paul Friedman, “Integrating Data from In Vitro New Approach Methodologies for Developmental Neurotoxicity,” Toxicological Sciences 187, no. February (2022): 62–79, https://doi.org/10.1093/toxsci/kfac018.
J. Blum, S. Masjosthusmann, K. Bartmann, et al., “Establishment of a human Cell-based In Vitro Battery to Assess Developmental Neurotoxicity Hazard of Chemicals,” Chemosphere 311 (2023): 137035, https://doi.org/10.1016/j.chemosphere.2022.137035.
P. Lein, E. Silbergeld, P. Locke, and A. M. Goldberg, “In Vitro and Other Alternative Approaches to Developmental Neurotoxicity Testing (DNT),” Environmental Toxicology and Pharmacology 19, no. 3 (2005): 735–744, https://doi.org/10.1016/J.ETAP.2004.12.035.
S. Coecke, A. M. Goldberg, S. Allen, et al., “Workgroup Report: Incorporating In Vitro Alternative Methods for Developmental Neurotoxicity into International Hazard and Risk Assessment Strategies,” Environmental Health Perspectives 115, no. 6 (2007): 924–931, https://doi.org/10.1289/ehp.9427.
K. M. Crofton, W. R. Mundy, P. J. Lein, et al., “Developmental Neurotoxicity Testing: Recommendations for Developing Alternative Methods for the Screening and Prioritization of Chemicals,” Altex 28, no. 1 (2011): 9–15, 10.14573/altex.2011.1.009.
E. Fritsche, “OECD/EFSA Workshop on Developmental Neurotoxicity (DNT): the Use of Non-animal Test Methods for Regulatory Purposes,” Altex 34, no. 2 (2017): 311–315, 10.14573/altex.1701171s.
K. Koch, K. Bartmann, J. Hartmann, et al., “Scientific Validation of Human Neurosphere Assays for Developmental Neurotoxicity Evaluation,” Frontiers in Toxicology 4 (2022): 7, https://doi.org/10.3389/ftox.2022.816370.
E. Cöllen, Y. Tanaskov, A. K. Holzer, et al., “Elements and Development Processes for Test Methods in Toxicology and human Health-relevant Life Science Research,” Altex 41, no. 1 (2024): 142–148, 10.14573/altex.2401041.
T. Hartung, S. Bremer, and S. Casati, “A Modular Approach to the ECVAM Principles on Test Validity,” Alternatives to Laboratory Animals 32, no. 5 (2004): 467–472, https://doi.org/10.1177/026119290403200503.
J. Blum, K. Bartmann, J. de Paula Souza, and E. Fritsche, “Developmental Neurotoxicity as a Case Example for a Six-step Framework for the Sustainable Regulatory Implementation of NAMs,” Current Opinion in Toxicology 42 (2025): 100528, https://doi.org/10.1016/j.cotox.2025.100528.
OECD. Guidance Document for Describing Non-Guideline In Vitro Test Methods. OECD; 2014. https://doi.org/10.1787/9789264274716-en.
OECD. OECD SERIES ON TESTING AND ASSESSMENT n34 Guidance document on the validation and international acceptance of new or updated test methods for hazard assessment 2005: 33.
A. Bal-Price, “Recommendation on Test Readiness Criteria for New Approach Methods in Toxicology: Exemplified for Developmental Neurotoxicity,” Altex 35, no. 3 (2018): 306–352, https://doi.org/10.14573/altex.1712081.
A. Lanzoni, A. F. Castoldi, G. E. N. Kass, et al., “Advancing human Health Risk Assessment,” EFSA Journal 17, no. S1 (2019): e170712, https://doi.org/10.2903/j.efsa.2019.e170712.
P. Marx-Stoelting, G. Rivière, M. Luijten, et al., “A Walk in the PARC: Developing and Implementing 21st Century Chemical Risk Assessment in Europe,” Archives of Toxicology 97, no. 3 (2023): 893–908, https://doi.org/10.1007/S00204-022-03435-7/FIGURES/2.
EMA. Qualification of novel methodologies for drug development: guidance to applicants EMA/CHMP/SAWP/72894/2008. Published online 2008, https://bit.ly/3RPtNLE.
OECD. Workshop Report on Operational and Financial Aspects of Validation, OECD Series on Testing and Assessment, No. 399. OECD Publ. Published online September 19, 2024, https://doi.org/10.1787/db9979eb-en.
M. N. Jacobs, S. Hoffmann, H. M. Hollnagel, et al., “Avoiding a Reproducibility Crisis in Regulatory Toxicology—On the Fundamental Role of Ring Trials,” Archives of Toxicology 98, no. 7 (2024): 2047–2063, https://doi.org/10.1007/S00204-024-03736-Z/TABLES/2.
A. J. van der Zalm, J. Barroso, P. Browne, et al., “A Framework for Establishing Scientific Confidence in New Approach Methodologies,” Archives of Toxicology 96, no. 11 (2022): 2865–2879, https://doi.org/10.1007/s00204-022-03365-4.
S. Masjosthusmann, D. Becker, B. Petzuch, et al., “A Transcriptome Comparison of Time-matched Developing human, Mouse and Rat Neural Progenitor Cells Reveals human Uniqueness,” Toxicology and Applied Pharmacology 354 (2018): 40–55, https://doi.org/10.1016/j.taap.2018.05.009.
S. Masjosthusmann, J. Blum, K. Bartmann, et al., “Establishment of an a Priori Protocol for the Implementation and Interpretation of an In-Vitro Testing Battery for the Assessment of Developmental Neurotoxicity,” EFSA Supporting Publications 17 (2020), https://doi.org/10.2903/sp.efsa.2020.en-1938.
A. Louvi, “Notch Signalling in Vertebrate Neural Development,” Nature Reviews Neuroscience 7, no. 2 (2006): 93–102, https://doi.org/10.1038/nrn1847.
T. Pierfelice, L. Alberi, and N. Gaiano, “Notch in the Vertebrate Nervous System: an Old Dog with New Tricks,” Neuron 69, no. 5 (2011): 840–855, https://doi.org/10.1016/J.NEURON.2011.02.031.
K. Yoon and N. Gaiano, “Notch Signaling in the Mammalian Central Nervous System: Insights from Mouse Mutants,” Nature Neuroscience 8, no. 6 (2005): 709–715, https://doi.org/10.1038/nn1475.
R. Zhang, A. Engler, and V. Taylor, “Notch: an Interactive Player in Neurogenesis and Disease,” Cell and Tissue Research 371, no. 1 (2018): 73–89, https://doi.org/10.1007/s00441-017-2641-9.
M. Vinken, E. Benfenati, F. Busquet, et al., “Safer Chemicals Using Less Animals: Kick-off of the European ONTOX Project,” Toxicology 458 (2021): 152846, https://doi.org/10.1016/j.tox.2021.152846.
B. Staumont, L. Ladeira, A. Gamba, et al., “Mapping Physiology: A Systems Biology Approach for the Development of Alternative Methods in Toxicology,” Altex 42 (2025), https://doi.org/10.14573/altex.2412241.
M. Ostaszewski, S. Gebel, I. Kuperstein, et al., “Community-driven Roadmap for Integrated Disease Maps,” Briefings in Bioinformatics 20, no. 2 (2019): 659–670, https://doi.org/10.1093/bib/bby024.
A. Mazein, M. Ostaszewski, I. Kuperstein, et al., “Systems Medicine Disease Maps: Community-driven Comprehensive Representation of Disease Mechanisms,” npj Systems Biology and Applications 4, no. 1 (2018): 1–10, https://doi.org/10.1038/s41540-018-0059-y.
A. Mazein, M. L. Acencio, I. Balaur, et al., “A Guide for Developing Comprehensive Systems Biology Maps of Disease Mechanisms: Planning, Construction and Maintenance,” Front Bioinforma 3 (2023): 1–13, https://doi.org/10.3389/fbinf.2023.1197310.
OECD. Users’ Handbook Supplement to the Guidance Document for Developing and Assessing Adverse Outcome Pathways. OECD Publ. 2018; OECD Serie, https://doi.org/10.1787/5jlv1m9d1g32-en.
C. Wittwehr, K. Audouze, T. Burgdorf, et al., “Society for the Advancement of AOPs Knowledgebase Interest Group,” SKIG Report (2025), https://doi.org/10.2760/7749010, 2023–2024.
H. J. Heusinkveld, Y. C. M. Staal, N. C. Baker, G. Daston, T. B. Knudsen, and A. Piersma, “An Ontology for Developmental Processes and Toxicities of Neural Tube Closure,” Reproductive Toxicology 99 (2021): 160–167, https://doi.org/10.1016/J.REPROTOX.2020.09.002.
J. H. Berkhout, J. A. Glazier, A. H. Piersma, et al., “A Computational Dynamic Systems Model for in Silico Prediction of Neural Tube Closure Defects,” Current Research Toxicology 18 (2024): 100210, https://doi.org/10.1016/j.crtox.2024.100210.
K. C. Dietz, J. J. Polanco, S. U. Pol, and F. J. Sim, “Targeting human Oligodendrocyte Progenitors for Myelin Repair,” Experimental Neurology 283 (2016): 489–500, https://doi.org/10.1016/J.EXPNEUROL.2016.03.017.
G. A. Van Norman, “Limitations of Animal Studies for Predicting Toxicity in Clinical Trials,” JACC: Basic to Translational Science 4, no. 7 (2019): 845–854, https://doi.org/10.1016/J.JACBTS.2019.10.008.
A. Punt, H. Bouwmeester, B. J. Blaauboer, et al., “New Approach Methodologies (NAMs) for Human-Relevant Biokinetics Predictions: Meeting the Paradigm Shift in Toxicology towards an Animal-Free Chemical Risk Assessment,” Altex 37, no. 4 (2020): 607–622, https://doi.org/10.14573/altex.2003242.
L. Beaulieu-Laroche, N. J. Brown, M. Hansen, et al., “Allometric Rules for Mammalian Cortical Layer 5 Neuron Biophysics,” Nature 600, no. 7888 (2021): 274–278, https://doi.org/10.1038/s41586-021-04072-3.
A. Hernández-Jerez, P. Adriaanse, A. Aldrich, et al., “Development of Integrated Approaches to Testing and Assessment (IATA) Case Studies on Developmental Neurotoxicity (DNT) Risk Assessment,” EFSA Journal 19, no. 6 (2021): 63, https://doi.org/10.2903/j.efsa.2021.6599.
M. Diaz-Cuadros, T. P. Miettinen, O. S. Skinner, et al., “Metabolic Regulation of Species-specific Developmental Rates,” Nature 613, no. 7944 (2023): 550–557, https://doi.org/10.1038/s41586-022-05574-4.
T. S. Klarić, I. Gudelj, G. Santpere, et al., “Human-specific Features and Developmental Dynamics of the Brain N-glycome,” Science Advances 9, no. 49 (2023), https://doi.org/10.1126/sciadv.adg2615.
I. T. Fiddes, G. A. Lodewijk, M. Mooring, et al., “Human-Specific NOTCH2NL Genes Affect Notch Signaling and Cortical Neurogenesis,” Cell 173, no. 6 (2018): 1356–1369, https://doi.org/10.1016/j.cell.2018.03.051.
I. K. Suzuki, D. Gacquer, R. Van Heurck, et al., “Human-Specific NOTCH2NL Genes Expand Cortical Neurogenesis through Delta/Notch Regulation,” Cell 173, no. 6 (2018): 1370–1384, https://doi.org/10.1016/j.cell.2018.03.067.
K. M. Walter, K. Dach, K. Hayakawa, et al., “Ontogenetic Expression of Thyroid Hormone Signaling Genes: An In Vitro and In Vivo Species Comparison,” PLoS ONE 14, no. 9 (2019): 1–26, https://doi.org/10.1371/journal.pone.0221230.
S. Masjosthusmann, C. Siebert, U. Hübenthal, F. Bendt, J. Baumann, and E. Fritsche, “Arsenite Interrupts Neurodevelopmental Processes of human and Rat Neural Progenitor Cells: the Role of Reactive Oxygen Species and Species-specific Antioxidative Defense,” Chemosphere 235 (2019): 447–456, https://doi.org/10.1016/j.chemosphere.2019.06.123.
J. Kapr, I. Scharkin, H. Ramachandran, et al., “HiPSC-derived 3D Neural Models Reveal Neurodevelopmental Pathomechanisms of the Cockayne Syndrome B,” Cellular and Molecular Life Sciences 81, no. 1 (2024): 368, https://doi.org/10.1007/s00018-024-05406-w.
V. K. Gribkoff and L. K. Kaczmarek, “The Need for New Approaches in CNS Drug Discovery: Why Drugs Have Failed, and What Can be Done to Improve Outcomes,” Neuropharmacology 120 (2017): 11–19, https://doi.org/10.1016/j.neuropharm.2016.03.021.
L. J. Marshall, J. Bailey, M. Cassotta, K. Herrmann, and F. Pistollato, “Poor Translatability of Biomedical Research Using Animals—A Narrative Review,” Alternatives to Laboratory Animals 51, no. 2 (2023): 102–135, https://doi.org/10.1177/02611929231157756.
D. Polioudakis, L. de la Torre-Ubieta, J. Langerman, et al., “A Single-Cell Transcriptomic Atlas of Human Neocortical Development during Mid-gestation,” Neuron 103, no. 5 (2019): 785–801, https://doi.org/10.1016/J.NEURON.2019.06.011.
U. C. Eze, A. Bhaduri, M. Haeussler, T. J. Nowakowski, and A. R. Kriegstein, “Single-cell Atlas of Early Human Brain Development Highlights Heterogeneity of human Neuroepithelial Cells and Early Radial Glia,” Nature Neuroscience 24, no. 4 (2021): 584–594, https://doi.org/10.1038/s41593-020-00794-1.
K. W. Kelley and S. P. Pașca, “Human Brain Organogenesis: toward a Cellular Understanding of Development and Disease,” Cell 185, no. 1 (2022): 42–61, https://doi.org/10.1016/J.CELL.2021.10.003.
M. Moors, T. D. Rockel, J. Abel, et al., “Human Neurospheres as Three-Dimensional Cellular Systems for Developmental Neurotoxicity Testing,” Environmental Health Perspectives 117, no. 7 (2009): 1131–1138, https://doi.org/10.1289/EHP.0800207.
D. Pamies, D. Wiersma, M. E. Katt, et al., “Human IPSC 3D Brain Model as a Tool to Study Chemical-induced Dopaminergic Neuronal Toxicity,” Neurobiology of Disease 169 (2022): 105719, https://doi.org/10.1016/j.nbd.2022.105719.
J. Hartmann, N. Henschel, K. Bartmann, et al., “Molecular and Functional Characterization of Different BrainSphere Models for Use in Neurotoxicity Testing on Microelectrode Arrays,” Cells 12, no. 9 (2023): 1270, https://doi.org/10.3390/CELLS12091270.
K. Ardhanareeswaran, J. Mariani, G. Coppola, A. Abyzov, and F. M. Vaccarino, “Human Induced Pluripotent Stem Cells for Modelling Neurodevelopmental Disorders,” Nature Reviews Neurology 13, no. 5 (2017): 265–278, https://doi.org/10.1038/nrneurol.2017.45.
M. Bershteyn, T. J. Nowakowski, A. A. Pollen, et al., “Human iPSC-Derived Cerebral Organoids Model Cellular Features of Lissencephaly and Reveal Prolonged Mitosis of Outer Radial Glia,” Cell Stem Cell 20, no. 4 (2017): 435–449.e4, https://doi.org/10.1016/J.STEM.2016.12.007.
E. F. Cohn, B. L. L. Clayton, M. Madhavan, et al., “Pervasive Environmental Chemicals Impair Oligodendrocyte Development,” Nature Neuroscience 27, no. 5 (2024): 836–845, https://doi.org/10.1038/s41593-024-01599-2.
C. A. Schneider, W. S. Rasband, and K. W. Eliceiri, “NIH Image to ImageJ: 25 Years of Image Analysis,” Nature Methods 9, no. 7 (2012): 671–675, https://doi.org/10.1038/nmeth.2089.
M. R. Schmuck, T. Temme, K. Dach, et al., “Omnisphero: A High-content Image Analysis (HCA) Approach for Phenotypic Developmental Neurotoxicity (DNT) Screenings of Organoid Neurosphere Cultures In Vitro,” Archives of Toxicology 91, no. 4 (2017): 2017–2028, https://doi.org/10.1007/s00204-016-1852-2.
N. Förster, J. Butke, H. E. Keßel, et al., “Reliable Identification and Quantification of Neural Cells in Microscopic Images of Neurospheres,” Cytometry Part A – The Journal of Quantitative Cell Science 101 (2021): 411–422, https://doi.org/10.1002/cyto.a.24514.
E. Fritsche, “Report on Integrated Testing Strategies for the Identification and Evaluation of Chemical Hazards Associated with the Developmental Neurotoxicity (DNT), to Facilitate Discussions at the Joint EFSA/OECD Workshop on DNT,” (2017), ENV/JM/MONO(2017)4/ANN1.
K. Koch, K. Schlüppmann, S. Hüsken, et al., “Nuclear Hormone Receptors Control Fundamental Processes of human Fetal Neurodevelopment: Basis for Endocrine Disruption Assessment,” Environment International 198 (2025): 109400, https://doi.org/10.1016/J.ENVINT.2025.109400.
J. Klose, J. Tigges, S. Masjosthusmann, et al., “TBBPA Targets Converging Key Events of human Oligodendrocyte Development Resulting in Two Novel AOPs,” Altex 38, no. 2 (2021): 215–234, https://doi.org/10.14573/altex.2007201.
J. A. Miller, S.-L. Ding, S. M. Sunkin, et al., “Transcriptional Landscape of the Prenatal Human Brain,” Nature 508, no. 7495 (2014): 199–206, https://doi.org/10.1038/nature13185.
A. Hardy, D. Benford, T. Halldorsson, et al., “Update: Use of the Benchmark Dose Approach in Risk Assessment,” EFSA J 15, no. 1 (2017): 04658, https://doi.org/10.2903/j.efsa.2017.4658.
C. Ritz, F. Baty, J. C. Streibig, and D. Gerhard, “Dose-Response Analysis Using,” PLoS ONE 10, no. 12 (2015): 0146021, https://doi.org/10.1371/journal.pone.0146021.
H. Keßel, S. Masjosthusmann, K. Bartmann, et al., “The Impact of Biostatistics on Hazard Characterization Using In Vitro Developmental Neurotoxicity Assays,” Altex 40, no. 4 (2023): 619–634, https://doi.org/10.14573/altex.2210171.
K. E. Carstens, A. Dönmez, J.-H. Hsieh, et al., “A Comparative Study of Biostatistical Pipelines for Benchmark Concentration Modeling of In Vitro Screening Assays,” Computational Toxicology 34 (2025): 100360, https://doi.org/10.1016/j.comtox.2025.100360.
A. Krebs, J. Nyffeler, J. Rahnenführer, and M. Leist, “Normalization of Data for Viability and Relative Cell Function Curves,” Altex 35, no. 2 (2018), https://doi.org/10.14573/altex.1803231.
F. Kappenberg, T. Brecklinghaus, W. Albrecht, et al., “Handling Deviating Control Values in Concentration-response Curves,” Archives of Toxicology 94, no. 11 (2020): 3787–3798, https://doi.org/10.1007/s00204-020-02913-0.
A. Krebs, J. Nyffeler, C. Karreman, et al., “Determination of Benchmark Concentrations and Their Statistical Uncertainty for Cytotoxicity Test Data and Functional In Vitro Assays,” Altex 37, no. 1 (2020): 155–163, https://doi.org/10.14573/altex.1912021.
M. D. Wilkinson, M. Dumontier, I. J. Aalbersberg, et al., “The FAIR Guiding Principles for Scientific Data Management and Stewardship,” Scientific Data 3, no. 1 (2016): 160018, https://doi.org/10.1038/sdata.2016.18.
N. N. Le, H. M, H. Mi, et al., “The Systems Biology Graphical Notation,” Nature Biotechnology 27, no. 8 (2009): 735–741, https://doi.org/10.1038/nbt.1558.
A. Funahashi, Y. Matsuoka, A. Jouraku, H. Kitano, and N. Kikuchi, “Celldesigner: a Modeling Tool for Biochemical Networks,” in Proceedings of the 2006 Winter Simulation Conference (IEEE, 2006), 1707–1712, https://doi.org/10.1109/WSC.2006.322946.
P. Gawron, M. Ostaszewski, V. Satagopam, et al., “MINERVA—A Platform for Visualization and Curation of Molecular Interaction Networks,” npj Systems Biology and Applications 2, no. 1 (2016): 1–6, https://doi.org/10.1038/npjsba.2016.20.
E. J. Calabrese, “Prostaglandins: Biphasic Dose Responses,” Critical Reviews in Toxicology 31, no. 4–5 (2001): 475–487, https://doi.org/10.1080/20014091111767.
M. A. Tegenge, T. D. Rockel, E. Fritsche, and G. Bicker, “Nitric Oxide Stimulates human Neural Progenitor Cell Migration via cGMP-mediated Signal Transduction,” Cellular and Molecular Life Sciences 68, no. 12 (2011): 2089–2099, https://doi.org/10.1007/S00018-010-0554-9.
M. Moors, J. E. Cline, J. Abel, and E. Fritsche, “ERK-dependent and -independent Pathways Trigger Human Neural Progenitor Cell Migration,” Toxicology and Applied Pharmacology 221, no. 1 (2007): 57–67, https://doi.org/10.1016/j.taap.2007.02.018.
Y. Zhou, H. Song, and M. G. li, “Genetics of Human Brain Development,” Nature Reviews Genetics 25, no. 1 (2024): 26–45, https://doi.org/10.1038/s41576-023-00626-5.
J. Klose, M. Pahl, K. Bartmann, et al., “Neurodevelopmental Toxicity Assessment of Flame Retardants Using a Human DNT In Vitro Testing Battery,” Cell Biology and Toxicology 10 (2021): 1–27, https://doi.org/10.1007/s10565-021-09603-2.
J. Klose, L. Li, M. Pahl, et al., “Application of the Adverse Outcome Pathway Concept for Investigating Developmental Neurotoxicity Potential of Chinese Herbal Medicines by Using human Neural Progenitor Cells In Vitro,” Cell Biology and Toxicology 1 (2022): 1–25, https://doi.org/10.1007/S10565-022-09730-4.
K. Dach, F. Bendt, U. Huebenthal, et al., “BDE-99 Impairs Differentiation of human and Mouse NPCs into the Oligodendroglial Lineage by Species-specific Modes of Action,” Scientific Reports 7, no. 44861 (2017), https://doi.org/10.1038/srep44861.
H. Ni, Z. Guo, Y. Wu, et al., “The Crucial Role That Hippocampus Cyclooxygenase-2 Plays in Memory,” European Journal of Neuroscience 58, no. 10 (2023): 4123–4136, https://doi.org/10.1111/ejn.16165.
H. Yang and C. Chen, “Cyclooxygenase-2 in Synaptic Signaling,” Current Pharmaceutical Design 14, no. 14 (2008): 1443–1451, https://doi.org/10.2174/138161208784480144.
C. T. Wong, N. Ussyshkin, E. Ahmad, R. Rai-Bhogal, H. Li, and D. A. Crawford, “Prostaglandin E 2 Promotes Neural Proliferation and Differentiation and Regulates Wnt Target Gene Expression,” Journal of Neuroscience Research 94, no. 8 (2016): 759–775, https://doi.org/10.1002/jnr.23759.
L. González-Llera, D. Sobrido-Cameán, A. Quelle-Regaldie, L. Sánchez, and A. Barreiro-Iglesias, “An In Vivo Drug Screen in Zebrafish Reveals That Cyclooxygenase 2-derived Prostaglandin D2Promotes Spinal Cord Neurogenesis,” Cell Proliferation 57, no. 5 (2024): 13594, https://doi.org/10.1111/cpr.13594.
S. M. Nam, J. W. Kim, D. Y. Yoo, et al., “Comparison of Pharmacological and Genetic Inhibition of Cyclooxygenase-2: Effects on Adult Neurogenesis in the Hippocampal Dentate Gyrus,” Journal of Veterinary Science 16, no. 3 (2015): 245–251, https://doi.org/10.4142/jvs.2015.16.3.245.
S. Grösch, I. Tegeder, E. Niederberger, L. Bräutigam, and G. Geisslinger, “COX-2 Independent Induction of Cell Cycle Arrest and Apoptosis in Colon Cancer Cells by the Selective COX-2 Inhibitor Celecoxib,” Faseb Journal 15, no. 14 (2001): 1–22, https://doi.org/10.1096/fj.01-0299fje.
L. D. Bo, H. G. Yuan, L. G. Xian, H. Qiu, Q. Mei, and H. G. Qing, “Celecoxib Induces Apoptosis and Cell-cycle Arrest in Nasopharyngeal Carcinoma Cell Lines via Inhibition of STAT3 Phosphorylation,” Acta Pharmacologica Sinica 33, no. 5 (2012): 682–690, https://doi.org/10.1038/aps.2012.18.
M. Motavaf and X. Piao, “Oligodendrocyte Development and Implication in Perinatal White Matter Injury,” Frontiers Cellular Neuroscience 15 (2021): 1–14, https://doi.org/10.3389/fncel.2021.764486.
J. R. Buser, J. Maire, A. Riddle, et al., “Arrested Preoligodendrocyte Maturation Contributes to Myelination Failure in Premature Infants,” Annals of Neurology 71, no. 1 (2012): 93–109, https://doi.org/10.1002/ana.22627.
L. R. Shiow, G. Favrais, L. Schirmer, et al., “Reactive Astrocyte COX2-PGE2 Production Inhibits Oligodendrocyte Maturation in Neonatal White Matter Injury,” Glia 65, no. 12 (2017): 2024–2037, https://doi.org/10.1002/glia.23212.
N. G. Carlson, S. Bellamkonda, L. Schmidt, et al., “The Role of the Prostaglandin E2 Receptors in Vulnerability of Oligodendrocyte Precursor Cells to Death,” Journal of Neuroinflammation 12, no. 1 (2015): 101, https://doi.org/10.1186/s12974-015-0323-7.
L. Li, Y. Yu, R. Hou, J. Hao, and J. Jiang, “Inhibiting the PGE 2 Receptor EP2 Mitigates Excitotoxicity and Ischemic Injury,” ACS Pharmacology & Translational Science 3, no. 4 (2020): 635–643, https://doi.org/10.1021/acsptsci.0c00040.
S. Mohan, S. Narumiya, and S. Doré, “Neuroprotective Role of Prostaglandin PGE2 EP2 Receptor in Hemin-mediated Toxicity,” Neurotoxicology 46 (2015): 53–59, https://doi.org/10.1016/j.neuro.2014.10.012.
Y. Liu, J. Guo, M. Matoga, M. Korotkova, P. J. Jakobsson, and A. Aguzzi, “NG2 Glia Protect against Prion Neurotoxicity by Inhibiting Microglia-to-neuron Prostaglandin E2 Signaling,” Nature Neuroscience 27, no. 8 (2024): 1534–1544, https://doi.org/10.1038/s41593-024-01663-x.
H. Wang, J. Xu, P. Lazarovici, R. Quirion, and W. Zheng, “cAMP Response Element-Binding Protein (CREB): A Possible Signaling Molecule Link in the Pathophysiology of Schizophrenia,” Frontiers in Molecular Neuroscience 11 (2018): 255, https://doi.org/10.3389/fnmol.2018.00255.
D. Gandolfi, S. Cerri, J. Mapelli, et al., “Activation of the CREB/c-Fos Pathway during Long-Term Synaptic Plasticity in the Cerebellum Granular Layer,” Frontiers in Cellular Neuroscience 11 (2017): 267377, https://doi.org/10.3389/fncel.2017.00184.
H. Chen, Y. Teng, X. Chen, et al., “Platelet-Derived Growth Factor (PDGF)-BB Protects Dopaminergic Neurons via Activation of Akt/ERK/CREB Pathways to Upregulate Tyrosine Hydroxylase,” CNS Neuroscience & Therapeutics 27, no. 11 (2021): 1300–1312, https://doi.org/10.1111/cns.13708.
B. E. Lonze and D. D. Ginty, “Function and Regulation of CREB Family Transcription Factors in the Nervous System,” Neuron 35, no. 4 (2002): 605–623, https://doi.org/10.1016/S0896-6273(02)00828-0.
D. Rudolph, A. Tafuri, P. Gass, G. J. Hämmerling, B. Arnold, and G. Schütz, “Impaired Fetal T Cell Development and Perinatal Lethality in Mice Lacking the cAMP Response Element Binding Protein,” Proceedings of the National Academy of Sciences 95, no. 8 (1998): 4481–4486, https://doi.org/10.1073/pnas.95.8.4481.
L. Pardo, L. M. Valor, A. Eraso-Pichot, et al., “CREB Regulates Distinct Adaptive Transcriptional Programs in Astrocytes and Neurons,” Scientific Reports 7, no. 1 (2017): 6390, https://doi.org/10.1038/s41598-017-06231-x.
J. Kim and B. K. Kaang, “Cyclic AMP Response Element-binding Protein (CREB) Transcription Factor in Astrocytic Synaptic Communication,” Frontiers Synaptic Neuroscience 14 (2023): 1059918, https://doi.org/10.3389/fnsyn.2022.1059918.
G. Lepski, C. E. Jannes, G. Nikkhah, and J. Bischofberger, “cAMP Promotes the Differentiation of Neural Progenitor Cells In Vitro via Modulation of Voltage-gated Calcium Channels,” Frontiers in Celularl Neuroscience 7 (2013): 155, https://doi.org/10.3389/FNCEL.2013.00155.
Z. Donders, I. J. Skorupska, E. Willems, et al., “Beyond PDE4 Inhibition: A Comprehensive Review on Downstream cAMP Signaling in the Central Nervous System,” Biomedicine & Pharmacotherapy 177 (2024): 117009, https://doi.org/10.1016/j.biopha.2024.117009.
H. Shiga, H. Asou, and E. Ito, “Advancement of Differentiation of Oligodendrocyte Progenitor Cells by a Cascade Including Protein Kinase A and Cyclic AMP-response Element Binding Protein,” Neuroscience Research 53, no. 4 (2005): 436–441, https://doi.org/10.1016/J.NEURES.2005.09.004.
C. Sato-Bigbee, S. Pal, and A. K. Chu, “Different Neuroligands and Signal Transduction Pathways Stimulate CREB Phosphorylation at Specific Developmental Stages along Oligodendrocyte Differentiation,” Journal of Neurochemistry 72, no. 1 (1999): 139–147, https://doi.org/10.1046/j.1471-4159.1999.0720139.x.
J. A. García-León, B. García-Díaz, K. Eggermont, et al., “Generation of Oligodendrocytes and Establishment of an All-human Myelinating Platform from Human Pluripotent Stem Cells,” Nature Protocols 15, no. 11 (2020): 3716–3744, https://doi.org/10.1038/s41596-020-0395-4.
A. G. P. Glebov-McCloud, W. S. Saide, M. E. Gaine, and S. Strack, “Protein Kinase A in Neurological Disorders,” Journal of Neurodevelopmental Disorders 16, no. 1 (2024): 9, https://doi.org/10.1186/s11689-024-09525-0.
Y. Ould Amer and E. Hebert-Chatelain, “Mitochondrial cAMP-PKA Signaling: What Do We Really Know?,” Biochimica et Biophysica Acta—Bioenergetics 1859, no. 9 (2018): 868–877, https://doi.org/10.1016/j.bbabio.2018.04.005.
B. Y. Hu, Z. W. Du, and S. C. Zhang, “Differentiation of human Oligodendrocytes from Pluripotent Stem Cells,” Nature Protocols 4, no. 11 (2009): 1614–1622, https://doi.org/10.1038/nprot.2009.186.
R. M. Marton, Y. Miura, S. A. Sloan, et al., “Differentiation and Maturation of Oligodendrocytes in human Three-dimensional Neural Cultures,” Nature Neuroscience 22, no. 3 (2019): 484–491, https://doi.org/10.1038/s41593-018-0316-9.
S. Passemard, F. Perez, P. Gressens, and G. V. El, “Endoplasmic Reticulum and Golgi Stress in Microcephaly,” Cell Stress 3, no. 12 (2019): 369–384, https://doi.org/10.15698/CST2019.12.206.
S. H. Kim, B. C. Lim, J. H. Chae, K. J. Kim, and Y. S. Hwang, “A Case of Rubinstein-Taybi Syndrome with a CREBbinding Protein Gene Mutation,” Korean Journal of Pediatrics 53, no. 6 (2010): 718–721, https://doi.org/10.3345/KJP.2010.53.6.718.
J. Van Gils, F. Magdinier, P. Fergelot, and L. D. R.-T. Syndrome, “A Model of Epigenetic Disorder,” Genes (Basel) 12, no. 7 (2021): 968, https://doi.org/10.3390/genes12070968.
M. J. Owen, M. C. O'Donovan, A. Thapar, and N. Craddock, “Neurodevelopmental Hypothesis of Schizophrenia,” British Journal of Psychiatry 198, no. 3 (2011): 173–175, https://doi.org/10.1192/bjp.bp.110.084384.
S. Finkbeiner, S. F. Tavazoie, A. Maloratsky, K. M. Jacobs, K. M. Harris, and M. E. Greenberg, “CREB: a Major Mediator of Neuronal Neurotrophin Responses,” Neuron 19, no. 5 (1997): 1031–1047, https://doi.org/10.1016/S0896-6273(00)80395-5/ASSET/056D3A4C-F210-4F8B-A73B-3B24A7EFE449/MAIN.ASSETS/GR12.JPG.
D. Pamies, K. Block, P. Lau, et al., “Rotenone Exerts Developmental Neurotoxicity in a human Brain Spheroid Model,” Toxicology and Applied Pharmacology 354 (2018): 101–114, https://doi.org/10.1016/j.taap.2018.02.003.
A. Schmitz, S. Dempewolf, S. Tan, G. Bicker, and M. Stern, “Developmental Neurotoxicity of Fipronil and Rotenone on a Human Neuronal In Vitro Test System,” Neurotoxicity Research 39, no. 4 (2021): 1189–1202, https://doi.org/10.1007/s12640-021-00364-8.
W. van der Stel, G. Carta, J. Eakins, et al., “New Approach Methods (NAMs) Supporting Read-Across: Two Neurotoxicity AOP-based IATA Case Studies,” Altex 38, no. 4 (2021): 615–635, https://doi.org/10.14573/altex.2103051.
A. K. Krug, N. V. Balmer, F. Matt, F. Schönenberger, D. Merhof, and M. Leist, “Evaluation of a human Neurite Growth Assay as Specific Screen for Developmental Neurotoxicants,” Archives of Toxicology 87, no. 12 (2013): 2215–2231, https://doi.org/10.1007/s00204-013-1072-y.
K. Bartmann, “A Human iPSC-Based In Vitro Neural Network Formation Assay to Investigate Neurodevelopmental Toxicity of Pesticides,” Altex 40, no. 3 (2023): 452–470, https://doi.org/10.14573/altex.2206031.
A. Terron, A. Bal-Price, A. Paini, et al., “An Adverse Outcome Pathway for Parkinsonian Motor Deficits Associated with Mitochondrial Complex I Inhibition,” Archives of Toxicology 92, no. 1 (2018): 41–82, https://doi.org/10.1007/s00204-017-2133-4.
D. Cabello-Rivera, H. Sarmiento-Soto, J. López-Barneo, and A. M. Muñoz-Cabello, “Mitochondrial Complex I Function Is Essential for Neural Stem/Progenitor Cells Proliferation and Differentiation,” Frontiers in Neuroscience 13 (2019), https://doi.org/10.3389/fnins.2019.00664.
L. Wang, Z. Yang, X. He, et al., “Mitochondrial Protein Dysfunction in Pathogenesis of Neurological Diseases,” Frontiers in Molecular Neuroscience 15 (2022), https://doi.org/10.3389/fnmol.2022.974480.
G. Inak, A. Rybak-Wolf, P. Lisowski, et al., “Defective Metabolic Programming Impairs Early Neuronal Morphogenesis in Neural Cultures and an Organoid Model of Leigh Syndrome,” Nature Communications 12, no. 1 (2021): 1929, https://doi.org/10.1038/s41467-021-22117-z.
T. Galera-Monge, F. Zurita-Díaz, I. Canals, et al., “Mitochondrial Dysfunction and Calcium Dysregulation in Leigh Syndrome Induced Pluripotent Stem Cell Derived Neurons,” International Journal of Molecular Sciences 21, no. 9 (2020): 3191, https://doi.org/10.3390/IJMS21093191.
S. Wullschleger, R. Loewith, and M. N. Hall, “TOR Signaling in Growth and Metabolism,” Cell 124, no. 3 (2006): 471–484, https://doi.org/10.1016/j.cell.2006.01.016.
D. Meng, A. R. Frank, and J. L. Jewell, “mTOR Signaling in Stem and Progenitor Cells,” Development (Cambridge, England) 145, no. 1 (2018): dev152595, https://doi.org/10.1242/dev.152595.
M. R. F. Reijnders, M. Kousi, G. M. van Woerden, et al., “Variation in a Range of mTOR-related Genes Associates with Intracranial Volume and Intellectual Disability,” Nature Communications 8, no. 1 (2017): 1–12, https://doi.org/10.1038/s41467-017-00933-6.
H. P. J. Everolimus, “Everolimus,” Clinical Cancer Research 16, no. 5 (2010): 1368–1372, https://doi.org/10.1158/1078-0432.CCR-09-1314.
N. Romanyuk, K. Sintakova, I. Arzhanov, et al., “mTOR Pathway Inhibition Alters Proliferation as Well as Differentiation of Neural Stem Cells,” Frontiers in Cellular Neuroscience 18 (2024): 1298182, https://doi.org/10.3389/fncel.2024.1298182.
M. Girodengo, S. K. Ultanir, and J. M. Bateman, “Mechanistic Target of Rapamycin Signaling in human Nervous System Development and Disease,” Frontiers in Molecular Neuroscience 15 (2022): 1005631, https://doi.org/10.3389/fnmol.2022.1005631.
L. N. Tran, S. K. Loew, and S. J. Franco, “Notch Signaling Plays a Dual Role in Regulating the Neuron-to-Oligodendrocyte Switch in the Developing Dorsal Forebrain,” The Journal of Neuroscience 43, no. 41 (2023): 6854–6871, https://doi.org/10.1523/JNEUROSCI.0144-23.2023.
E. Cau and P. Blader, “Notch Activity in the Nervous System: To Switch or Not Switch?,” Neural Development 4, no. 1 (2009): 36, https://doi.org/10.1186/1749-8104-4-36.
L. Grandbarbe, J. Bouissac, M. Rand, M. Hrabé de Angelis, S. Artavanis-Tsakonas, and E. Mohier, “Delta-Notch Signaling Controls the Generation of Neurons/Glia from Neural Stem Cells in a Stepwise Process,” Development (Cambridge, England) 130, no. 7 (2003): 1391–1402, https://doi.org/10.1242/dev.00374.
L. Borghese, D. Dolezalova, T. Opitz, et al., “Inhibition of Notch Signaling in Human Embryonic Stem Cell–Derived Neural Stem Cells Delays G1/S Phase Transition and Accelerates Neuronal Differentiation In Vitro and In Vivo,” Stem Cells 28, no. 5 (2010): 955–964, https://doi.org/10.1002/stem.408.
T. Q. Crawford and H. Roelink, “The Notch Response Inhibitor DAPT Enhances Neuronal Differentiation in Embryonic Stem Cell-Derived Embryoid Bodies Independently of Sonic Hedgehog Signaling,” Developmental Dynamics 236, no. 3 (2007): 886–892, https://doi.org/10.1002/dvdy.21083.
Z. Peng, X. Li, M. Fu, et al., “Inhibition of Notch1 Signaling Promotes Neuronal Differentiation and Improves Functional Recovery in Spinal Cord Injury through Suppressing the Activation of Ras Homolog family Member A,” Journal of Neurochemistry 150, no. 6 (2019): 709–722, https://doi.org/10.1111/jnc.14833.
J. L. Snyder, C. A. Kearns, and B. Appel, “Fbxw7 regulates Notch to Control Specification of Neural Precursors for Oligodendrocyte Fate,” Neural Development 7, no. 1 (2012): 15, https://doi.org/10.1186/1749-8104-7-15.
J. J. Moffat, M. Ka, E. M. Jung, and W. Y. Kim, “Genes and Brain Malformations Associated with Abnormal Neuron Positioning,” Molecular Brain 8, no. 1 (2015): 72, https://doi.org/10.1186/s13041-015-0164-4.
L. Pisciotta, V. Capra, A. Accogli, et al., “Epileptic Encephalopathy in Adams–Oliver Syndrome Associated to a New DOCK6 Mutation: a Peculiar Behavioral Phenotype,” Neuropediatrics 49, no. 3 (2018): 217–221, https://doi.org/10.1055/s-0038-1639372.
T. Ozcelik, N. Akarsu, E. Uz, et al., “Mutations in the Very Low-density Lipoprotein Receptor VLDLR Cause Cerebellar Hypoplasia and Quadrupedal Locomotion in Humans,” Proceedings of the National Academy of Sciences 105, no. 11 (2008): 4232–4236, https://doi.org/10.1073/pnas.0710010105.
F. Majolo, D. R. Marinowic, D. C. Machado, and J. C. Da Costa, “Notch Signaling in Human iPS-Derived Neuronal Progenitor Lines from Focal Cortical Dysplasia Patients,” International Journal of Developmental Neuroscience 69, no. 1 (2018): 112–118, https://doi.org/10.1016/j.ijdevneu.2018.07.006.
S. Keilani and K. Sugaya, “Reelin Induces a Radial Glial Phenotype in human Neural Progenitor Cells by Activation of Notch-1,” BMC Developmental Biology 8, no. 1 (2008): 69, https://doi.org/10.1186/1471-213X-8-69.
Y. Jossin, “Reelin Functions, Mechanisms of Action and Signaling Pathways during Brain Development and Maturation,” Biomolecules 10, no. 6 (2020): 964, https://doi.org/10.3390/biom10060964.
S. C. Su and L. H. Tsai, “Cyclin-Dependent Kinases in Brain Development and Disease,” Annual Review of Cell and Developmental Biology 27, no. 1 (2011): 465–491, https://doi.org/10.1146/annurev-cellbio-092910-154023.
Y. Shinmyo, Y. Terashita, T. A. Dinh Duong, et al., “Folding of the Cerebral Cortex Requires Cdk5 in Upper-Layer Neurons in Gyrencephalic Mammals,” Cell Reports 20, no. 9 (2017): 2131–2143, https://doi.org/10.1016/j.celrep.2017.08.024.
D. Magen, A. Ofir, L. Berger, et al., “Autosomal Recessive Lissencephaly with Cerebellar Hypoplasia Is Associated with a Loss-of-function Mutation in CDK5,” Human Genetics 134, no. 3 (2015): 305–314, https://doi.org/10.1007/S00439-014-1522-5/FIGURES/3.
P. H. Chen, X. Chen, and X. He, “Platelet-derived Growth Factors and Their Receptors: Structural and Functional Perspectives,” Biochimica et Biophysica Acta (BBA)—Proteins and Proteomics 1834, no. 10 (2013): 2176–2186, https://doi.org/10.1016/j.bbapap.2012.10.015.
A. Erlandsson, M. Enarsson, and K. Forsberg-Nilsson, “Immature Neurons from CNS Stem Cells Proliferate in Response to Platelet-Derived Growth Factor,” The Journal of Neuroscience 21, no. 10 (2001): 3483–3491, https://doi.org/10.1523/JNEUROSCI.21-10-03483.2001.
S. Sil, P. Periyasamy, A. Thangaraj, E. T. Chivero, and S. Buch, “PDGF/PDGFR Axis in the Neural Systems,” Molecular Aspects of Medicine 62 (2018): 63–74, https://doi.org/10.1016/j.mam.2018.01.006.
S. A. Lewandowski, L. Fredriksson, and D. A. Lawrence, “Pharmacological Targeting of the PDGF-CC Signaling Pathway for Blood–brain Barrier Restoration in Neurological Disorders,” Pharmacology & Therapeutics 167 (2016): 108–119, https://doi.org/10.1016/J.PHARMTHERA.2016.07.016.
L. C. D. Smyth, B. Highet, D. Jansson, et al., “Characterisation of PDGF-BB:PDGFRβ Signalling Pathways in human Brain Pericytes: Evidence of Disruption in Alzheimer's Disease,” Communications Biology 5, no. 1 (2022): 235, https://doi.org/10.1038/s42003-022-03180-8.
O. Zachrisson, M. Zhao, A. Andersson, et al., “Restorative Effects of Platelet Derived Growth Factor-BB in Rodent Models of Parkinson's Disease,” Journal of Parkinson's Disease 1, no. 1 (2011): 49–63, https://doi.org/10.3233/JPD-2011-0003.
L. Zhou, C.-Y. Shao, Y.-J. Xie, et al., “Gab1 mediates PDGF Signaling and Is Essential to Oligodendrocyte Differentiation and CNS Myelination,” Elife 9 (2020), https://doi.org/10.7554/eLife.52056.
L. Wang, K. Zhou, Z. Fu, et al., “Brain Development and Akt Signaling: the Crossroads of Signaling Pathway and Neurodevelopmental Diseases,” Journal of Molecular Neuroscience 61, no. 3 (2017): 379–384, https://doi.org/10.1007/S12031-016-0872-Y/FIGURES/1.
K. Nourbakhsh and S. Yadav, “Kinase Signaling in Dendritic Development and Disease,” Frontiers in Cellular Neuroscience 15 (2021): 624648, https://doi.org/10.3389/fncel.2021.624648.
D. E. Read and A. M. Gorman, “Involvement of Akt in Neurite Outgrowth,” Cellular and Molecular Life Sciences 66, no. 18 (2009): 2975–2984, https://doi.org/10.1007/s00018-009-0057-8.
Y. Kang, Y. Zhou, Y. Li, et al., “A Human Forebrain Organoid Model of Fragile X Syndrome Exhibits Altered Neurogenesis and Highlights New Treatment Strategies,” Nature Neuroscience 24, no. 10 (2021): 1377–1391, https://doi.org/10.1038/S41593-021-00913-6.
N. Raj, Z. T. McEachin, W. Harousseau, et al., “Cell-type-specific Profiling of Human Cellular Models of Fragile X Syndrome Reveal PI3K-dependent Defects in Translation and Neurogenesis,” Cell Reports 35, no. 2 (2021): 108991, https://doi.org/10.1016/J.CELREP.2021.108991.
M. E. Doers, M. T. Musser, R. Nichol, et al., “iPSC-Derived Forebrain Neurons from FXS Individuals Show Defects in Initial Neurite Outgrowth,” Stem Cells and Development 23, no. 15 (2014): 1777–1787, https://doi.org/10.1089/SCD.2014.0030.
C. M. Dias, B. Issac, L. Sun, et al., “Glial Dysregulation in the Human Brain in Fragile X-associated Tremor/Ataxia Syndrome,” Proceedings of the National Academy of Sciences 120, no. 23 (2023): 2300052120, https://doi.org/10.1073/pnas.2300052120.
R. F. Hevner, “Brain Overgrowth in Disorders of RTK–PI3K–AKT Signaling: A Mosaic of Malformations,” Seminars in Perinatology 39, no. 1 (2015): 36–43, https://doi.org/10.1053/J.SEMPERI.2014.10.006.
R. Oegema, T. S. Barakat, M. Wilke, et al., “International Consensus Recommendations on the Diagnostic Work-up for Malformations of Cortical Development,” Nature Reviews Neurology 16, no. 11 (2020): 618–635, https://doi.org/10.1038/s41582-020-0395-6.
A. Represa, “Why Malformations of Cortical Development Cause Epilepsy,” Frontiers in Neuroscience 13 (2019): 250, https://doi.org/10.3389/FNINS.2019.00250/BIBTEX.
K. Kisoh, H. Hayashi, M. Arai, M. Orita, B. Yuan, and N. Takagi, “Possible Involvement of PI3-K/Akt-Dependent GSK-3β Signaling in Proliferation of Neural Progenitor Cells after Hypoxic Exposure,” Molecular Neurobiology 56, no. 3 (2019): 1946–1956, https://doi.org/10.1007/s12035-018-1216-4.
Y. Wu, H. Peng, M. Cui, N. P. Whitney, Y. Huang, and J. C. Zheng, “CXCL12 increases human Neural Progenitor Cell Proliferation through Akt-1/FOXO3a Signaling Pathway,” Journal of Neurochemistry 109, no. 4 (2009): 1157–1167, https://doi.org/10.1111/j.1471-4159.2009.06043.x.
S. Yu, X. Zhang, Z. Xu, and C. Hu, “Melatonin Promotes Proliferation of Neural Stem Cells from Adult Mouse Spinal Cord via the PI3K/AKT Signaling Pathway,” FEBS Letters 593, no. 14 (2019): 1751–1762, https://doi.org/10.1002/1873-3468.13458.
W. S. Chan, A. Sideris, J. J. Sutachan, G. J. V. Montoya, T. J. J. Blanck, and E. Recio-Pinto, “Differential Regulation of Proliferation and Neuronal Differentiation in Adult Rat Spinal Cord Neural Stem/Progenitors by ERK1/2, Akt, and PLCγ,” Frontiers in Molecular Neuroscience 6, no. AUG (2013): 53686, https://doi.org/10.3389/fnmol.2013.00023.
M. Wang, H. Hayashi, I. Horinokita, et al., “Role of Senkyunolide I in the Promotion of Neural Stem/Progenitor Cell Proliferation via the Akt/β-catenin Pathway,” Biomedicine & Pharmacotherapy 168 (2023): 115683, https://doi.org/10.1016/j.biopha.2023.115683.
J. H. Rhim, X. Luo, D. Gao, et al., “Cell Type-dependent Erk-Akt Pathway Crosstalk Regulates the Proliferation of Fetal Neural Progenitor Cells,” Scientific Reports 6, no. 1 (2016): 26547, https://doi.org/10.1038/srep26547.
J. Peltier, A. O'Neill, and D. V. Schaffer, “PI3K/Akt and CREB Regulate Adult Neural Hippocampal Progenitor Proliferation and Differentiation,” Developmental Neurobiology 67, no. 10 (2007): 1348–1361, https://doi.org/10.1002/dneu.20506.
M. Costa-Mattioli and L. M. Monteggia, “mTOR Complexes in Neurodevelopmental and Neuropsychiatric Disorders,” Nature Neuroscience 16, no. 11 (2013): 1537–1543, https://doi.org/10.1038/nn.3546.
S. Grade, F. Agasse, L. Bernardino, C. G. Silva, L. Cortes, and J. O. Malva, “Functional Identification of Neural Stem Cell–Derived Oligodendrocytes by Means of Calcium Transients Elicited by Thrombin,” Rejuvenation Research 13, no. 1 (2010): 27–37, https://doi.org/10.1089/rej.2009.0889.
D. S. Kang, Y. R. Yang, C. Lee, S. Kim, S. H. Ryu, and P. G. Suh, “Roles of Phosphoinositide-specific Phospholipase Cγ1 in Brain Development,” Advances in Biological Regulation 60 (2016): 167–173, https://doi.org/10.1016/j.jbior.2015.10.002.
K. H. Lim, S. Yang, S. H. Kim, E. Ko, M. Kang, and J. Y. Joo, “Cryptic Mutations of PLC family Members in Brain Disorders: Recent Discoveries and a Deep-learning-based Approach,” Brain 146, no. 4 (2023): 1267–1280, https://doi.org/10.1093/brain/awac451.
F. He, W. Ge, K. Martinowich, et al., “A Positive Autoregulatory Loop of Jak-STAT Signaling Controls the Onset of Astrogliogenesis,” Nature Neuroscience 8, no. 5 (2005): 616–625, https://doi.org/10.1038/nn1440.
S. Fukuda, M. Abematsu, H. Mori, et al., “Potentiation of Astrogliogenesis by STAT3-Mediated Activation of Bone Morphogenetic Protein-Smad Signaling in Neural Stem Cells,” Molecular and Cellular Biology 27, no. 13 (2007): 4931–4937, https://doi.org/10.1128/MCB.02435-06.
F. Cao, R. Hata, P. Zhu, N. K. ichi, and M. Sakanaka, “Conditional Deletion of Stat3 Promotes Neurogenesis and Inhibits Astrogliogenesis in Neural Stem Cells,” Biochemical and Biophysical Research Communications 394, no. 3 (2010): 843–847, https://doi.org/10.1016/J.BBRC.2010.03.092.
R. Kanski, M. E. van Strien, P. van Tijn, and E. M. Hol, “A Star Is Born: New Insights into the Mechanism of Astrogenesis,” Cellular and Molecular Life Sciences 71, no. 3 (2014): 433–447, https://doi.org/10.1007/s00018-013-1435-9.
A. S. Spreng, M. Brüll, H. Leisner, I. Suciu, and M. Leist, “Distinct and Dynamic Transcriptome Adaptations of iPSC-Generated Astrocytes after Cytokine Stimulation,” Cells 11, no. 17 (2022): 2644, https://doi.org/10.3390/cells11172644.
S. Dziennis and N. J. Alkayed, “Role of Signal Transducer and Activator of Transcription 3 in Neuronal Survival and Regeneration,” Reviews in the Neurosciences 19, no. 4–5 (2008): 341, https://doi.org/10.1515/REVNEURO.2008.19.4-5.341.
S. Pramanik, Y. A. Sulistio, and K. Heese, “Neurotrophin Signaling and Stem Cells—Implications for Neurodegenerative Diseases and Stem Cell Therapy,” Molecular Neurobiology 54, no. 9 (2017): 7401–7459, https://doi.org/10.1007/s12035-016-0214-7.
T. Sonoyama, L. K. J. Stadler, M. Zhu, et al., “Human BDNF/TrkB Variants Impair Hippocampal Synaptogenesis and Associate with Neurobehavioural Abnormalities,” Scientific Reports 10, no. 1 (2020): 1–14, https://doi.org/10.1038/s41598-020-65531-x.
H. J. Kang, Y. I. Kawasawa, F. Cheng, et al., “Spatio-temporal Transcriptome of the human Brain,” Nature 478, no. 7370 (2011): 483–489, https://doi.org/10.1038/nature10523.
E. Di Consiglio, F. Pistollato, E. Mendoza-De Gyves, A. Bal-Price, and E. Testai, “Integrating Biokinetics and In Vitro Studies to Evaluate Developmental Neurotoxicity Induced by Chlorpyrifos in human iPSC-derived Neural Stem Cells Undergoing Differentiation towards Neuronal and Glial Cells,” Reproductive Toxicology 98 (2020): 174–188, https://doi.org/10.1016/J.REPROTOX.2020.09.010.
N. Davidsen, A. J. Lauvås, O. Myhre, et al., “Exposure to human Relevant Mixtures of Halogenated Persistent Organic Pollutants (POPs) Alters Neurodevelopmental Processes in Human Neural Stem Cells Undergoing Differentiation,” Reproductive Toxicology 100 (2021): 17–34, https://doi.org/10.1016/j.reprotox.2020.12.013.
P. Kowiański, G. Lietzau, E. Czuba, M. Waśkow, A. Steliga, and J. Moryś, “BDNF: A Key Factor with Multipotent Impact on Brain Signaling and Synaptic Plasticity,” Cellular and Molecular Neurobiology 38, no. 3 (2018): 579–593, https://doi.org/10.1007/s10571-017-0510-4.
T. A. Mishchenko, E. V. Mitroshina, A. V. Usenko, et al., “Features of Neural Network Formation and Their Functions in Primary Hippocampal Cultures in the Context of Chronic TrkB Receptor System Influence,” Frontiers Physiology 10, no. JAN (2019), https://doi.org/10.3389/FPHYS.2018.01925/FULL.
T. Tal, O. Myhre, E. Fritsche, et al., “New Approach Methods to Assess Developmental and Adult Neurotoxicity for Regulatory Use: A PARC Work Package 5 Project,” Frontiers in Toxicology 6 (2024): 1359507, https://doi.org/10.3389/ftox.2024.1359507.
J. Liu, Q. Xiao, J. Xiao, et al., “Wnt/β-catenin Signalling: Function, Biological Mechanisms, and Therapeutic Opportunities,” Signal Transduction and Targeted Therapy 7, no. 1 (2022): 3, https://doi.org/10.1038/s41392-021-00762-6.
J. Huang, X. Guo, W. Li, and H. Zhang, “Activation of Wnt/β-catenin Signalling via GSK3 Inhibitors Direct Differentiation of human Adipose Stem Cells into Functional Hepatocytes,” Scientific Reports 7, no. 1 (2017): 40716, https://doi.org/10.1038/srep40716.
D. Wu and W. Pan, “GSK3: A Multifaceted Kinase in Wnt Signaling,” Trends in Biochemical Sciences 35, no. 3 (2010): 161–168, https://doi.org/10.1016/j.tibs.2009.10.002.
S. Q. Zhang, K. L. Lin, C. Y. Law, et al., “Oleanolic Acid Enhances Neural Stem Cell Migration, Proliferation, and Differentiation In Vitro by Inhibiting GSK3β Activity,” Cell Death Discovery 4, no. 1 (2018): 48, https://doi.org/10.1038/s41420-018-0111-0.
V. Iefremova, G. Manikakis, O. Krefft, et al., “An Organoid-Based Model of Cortical Development Identifies Non-Cell-Autonomous Defects in Wnt Signaling Contributing to Miller-Dieker Syndrome,” Cell Reports 19, no. 1 (2017): 50–59, https://doi.org/10.1016/j.celrep.2017.03.047.
A. López-Tobón, C. E. Villa, C. Cheroni, et al., “Human Cortical Organoids Expose a Differential Function of GSK3 on Cortical Neurogenesis,” Stem Cell Reports 13, no. 5 (2019): 847, https://doi.org/10.1016/J.STEMCR.2019.09.005.
S. S. Rosenberg and J. R. Chan, “Modulating Myelination: Knowing When to Say Wnt: Figure 1,” Genes & Development 23, no. 13 (2009): 1487–1493, https://doi.org/10.1101/GAD.1824009.
H.-H. Tsai, J. Niu, R. Munji, et al., “Oligodendrocyte Precursors Migrate along Vasculature in the Developing Nervous System,” Science 351, no. 6271 (2016): 379–384, https://doi.org/10.1126/science.aad3839.
M. O. Caracci, M. E. Avila, F. A. Espinoza-Cavieres, L. Hr, G. D. Ugarte, and G. V. De Ferrari, “Wnt/β-Catenin-Dependent Transcription in Autism Spectrum Disorders,” Frontiers in Molecular Neuroscience 14 (2021): 263, https://doi.org/10.3389/FNMOL.2021.764756/BIBTEX.
W. Zhuang, T. Ye, W. Wang, W. Song, and T. Tan, “CTNNB1 in Neurodevelopmental Disorders,” Frontiers in Psychiatry 14 (2023): 401, https://doi.org/10.3389/fpsyt.2023.1143328.
Y. Zhu, A. M. M. Sousa, T. Gao, et al., “Spatiotemporal Transcriptomic Divergence across human and Macaque Brain Development,” Science 362, no. 6420 (2018), https://doi.org/10.1126/science.aat8077.
B. Y. Hu, Z. W. Du, X. J. Li, M. Ayala, and S. C. Zhang, “Human Oligodendrocytes from Embryonic Stem Cells: Conserved SHH Signaling Networks and Divergent FGF Effects,” Development (Cambridge, England) 136, no. 9 (2009): 1443–1452, https://doi.org/10.1242/DEV.029447.
T. M. Przytycka and J. Andrews, “Systems-biology Dissection of Eukaryotic Cell Growth,” BMC Biology 8, no. 1 (2010): 62, https://doi.org/10.1186/1741-7007-8-62.
M. Apte and A. Kumar, “Correlation of Mutated Gene and Signalling Pathways in ASD,” IBRO Neuroscience Reports 14 (2023): 384–392, https://doi.org/10.1016/j.ibneur.2023.03.011.
S. Nisar and M. Haris, “Neuroimaging Genetics Approaches to Identify New Biomarkers for the Early Diagnosis of Autism Spectrum Disorder,” Molecular Psychiatry 17 (2023): 1–14, https://doi.org/10.1038/s41380-023-02060-9.
J. A. Bachman, B. M. Gyori, and P. K. Sorger, “Automated Assembly of Molecular Mechanisms at Scale from Text Mining and Curated Databases,” Molecular Systems Biology 19, no. 5 (2023): 11325, https://doi.org/10.15252/msb.202211325.
A. Niarakis, M. Ostaszewski, A. Mazein, et al., “A Versatile and Interoperable Computational Framework for the Analysis and Modeling of COVID-19 Disease Mechanisms,” BioRxiv (2022), https://doi.org/10.1101/2022.12.17.520865.
A. Zagare, A. Hemedan, C. Almeida, et al., “Insulin Resistance Is a Modifying Factor for Parkinson's Disease,” Movement Disorders 40, no. 1 (2025): 67–76, https://doi.org/10.1002/mds.30039.
B. Elbaz and B. Popko, “Molecular Control of Oligodendrocyte Development,” Trends in Neurosciences 42, no. 4 (2019): 263–277, https://doi.org/10.1016/J.TINS.2019.01.002.
A. K. Santos, M. S. Vieira, R. Vasconcellos, V. A. M. Goulart, A. H. Kihara, and R. R. Resende, “Decoding Cell Signalling and Regulation of Oligodendrocyte Differentiation,” Seminars in Cell & Developmental Biology 95 (2019): 54–73, https://doi.org/10.1016/J.SEMCDB.2018.05.020.
J. D. Iroegbu, O. K. Ijomone, O. M. Femi-Akinlosotu, and O. M. Ijomone, “ERK/MAPK Signalling in the Developing Brain: Perturbations and Consequences,” Neuroscience & Biobehavioral Reviews 131 (2021): 792–805, https://doi.org/10.1016/j.neubiorev.2021.10.009.
P. C. Pao and L. H. Tsai, “Three Decades of Cdk5,” Journal of Biomedical Science 28, no. 1 (2021): 79, https://doi.org/10.1186/s12929-021-00774-y.
R. D. Castro-Torres, J. Olloquequi, A. Parcerisas, et al., “JNK Signaling and Its Impact on Neural Cell Maturation and Differentiation,” Life Sciences 350 (2024): 122750, https://doi.org/10.1016/j.lfs.2024.122750.
S. Ribeiro and R. M. Sherrard, “Cerebellum and Neurodevelopmental Disorders: RORα is a Unifying Force,” Frontiers in Cellular Neuroscience 17 (2023): 1108339, https://doi.org/10.3389/fncel.2023.1108339.
A. Sayad, R. Noroozi, M. D. Omrani, M. Taheri, and S. Ghafouri-Fard, “Retinoic Acid-related Orphan Receptor Alpha (RORA) Variants Are Associated with Autism Spectrum Disorder,” Metabolic Brain Disease 32, no. 5 (2017): 1595–1601, https://doi.org/10.1007/s11011-017-0049-6.
H. H. Freeze, E. A. Eklund, B. G. Ng, and M. C. Patterson, “Neurological Aspects of Human Glycosylation Disorders,” Annual Review of Neuroscience 38, no. 1 (2015): 105–125, https://doi.org/10.1146/annurev-neuro-071714-034019.
S. Proença, B. I. Escher, F. C. Fischer, et al., “Effective Exposure of Chemicals in In Vitro Cell Systems: a Review of Chemical Distribution Models,” Toxicology In Vitro: An International Journal Published in Association with Bibra 73 (2021): 105133, https://doi.org/10.1016/j.tiv.2021.105133.
M. Becker, F. Mastropasqua, J. P. Reising, et al., “Presynaptic Dysfunction in CASK-related Neurodevelopmental Disorders,” Translational Psychiatry 10, no. 1 (2020): 1–17, https://doi.org/10.1038/s41398-020-00994-0.
L. Kuznitsov-Yanovsky, G. Shapira, L. Gildin, N. Shomron, and D. Ben-Yosef, “Transcriptomic Analysis of Human Fragile X Syndrome Neurons Reveals Neurite Outgrowth Modulation by the TGFβ/BMP Pathway,” International Journal of Molecular Sciences 23, no. 16 (2022): 9278, https://doi.org/10.3390/ijms23169278.
P. R. Blackburn, C. J. Zepeda-Mendoza, T. M. Kruisselbrink, et al., “Variable Expressivity of Syndromic BMP4-related Eye, Brain, and Digital Anomalies: A Review of the Literature and Description of Three New Cases,” European Journal of Human Genetics 27, no. 9 (2019): 1379–1388, https://doi.org/10.1038/S41431-019-0423-4.
R. Sethi, N. Gómez-Coronado, A. J. Walker, et al., “Neurobiology and Therapeutic Potential of Cyclooxygenase-2 (COX-2) Inhibitors for Inflammation in Neuropsychiatric Disorders,” Frontiers in Psychiatry 10 (2019): 425455, https://doi.org/10.3389/fpsyt.2019.00605.
Q. Bu, A. Wang, H. Hamzah, et al., “CREB Signaling Is Involved in Rett Syndrome Pathogenesis,” The Journal of Neuroscience 37, no. 13 (2017): 3671–3685, https://doi.org/10.1523/JNEUROSCI.3735-16.2017.
D. E. Ehrlich and S. A. Josselyn, “Plasticity-related Genes in Brain Development and Amygdala-dependent Learning,” Genes, Brain and Behavior 15, no. 1 (2016): 125–143, https://doi.org/10.1111/gbb.12255.
S. Delhaye and B. Bardoni, “Role of Phosphodiesterases in the Pathophysiology of Neurodevelopmental Disorders,” Molecular Psychiatry 26, no. 9 (2021): 4570–4582, https://doi.org/10.1038/s41380-020-00997-9.
A. J. Russo, “Increased Epidermal Growth Factor Receptor (EGFR) Associated with Hepatocyte Growth Factor (HGF) and Symptom Severity in Children with Autism Spectrum Disorders (ASDs),” Journal of Central Nervous System Disease 6 (2014): 79–83, https://doi.org/10.4137/JCNSD.S13767.
A. J. Russo, “Decreased Epidermal Growth Factor (EGF) Associated with HMGB1 and Increased Hyperactivity in Children with Autism,” Biomarker Insights 8 (2013): 35–41, https://doi.org/10.4137/BMI.S11270.
C. Sabino, D. Bender, M. L. Herrlein, and E. Hildt, “The Epidermal Growth Factor Receptor Is a Relevant Host Factor in the Early Stages of The Zika Virus Life Cycle In Vitro,” Journal of Virology 95, no. 20 (2021), https://doi.org/10.1128/JVI.01195-21.
J. A. Carpentieri, A. Di Cicco, M. Lampic, et al., “Endosomal Trafficking Defects Alter Neural Progenitor Proliferation and Cause Microcephaly,” Nature Communications 13, no. 1 (2022): 16, https://doi.org/10.1038/s41467-021-27705-7.
J. Zhang, M. Liu, Z. Zhang, et al., “Genotypic Spectrum and Natural History of Cavitating Leukoencephalopathies in Childhood,” Pediatric Neurology 94 (2019): 38–47, https://doi.org/10.1016/j.pediatrneurol.2019.01.002.
H. Ganesan, V. Balasubramanian, M. Iyer, et al., “mTOR Signalling Pathway—A Root Cause for Idiopathic Autism?,” BMB Reports 52, no. 7 (2019): 424–433, https://doi.org/10.5483/BMBRep.2019.52.7.137.
S. Prem, B. Dev, C. Peng, et al., “Dysregulation of mTOR Signaling Mediates Common Neurite and Migration Defects in both Idiopathic and 16p11.2 Deletion Autism Neural Precursor Cells,” Elife 13 (2024), https://doi.org/10.7554/eLife.82809.
D. N. Franz and J. K. Capal, “MTOR Inhibitors in the Pharmacologic Management of Tuberous Sclerosis Complex and Their Potential Role in Other Rare Neurodevelopmental Disorders,” Orphanet Journal of Rare Diseases 12, no. 1 (2017): 1–9, https://doi.org/10.1186/S13023-017-0596-2/FIGURES/1.
T. S. Zimmer, D. W. M. Broekaart, V. E. Gruber, E. A. van Vliet, A. Mühlebner, and E. Aronica, “Tuberous Sclerosis Complex as Disease Model for Investigating mTOR-Related Gliopathy during Epileptogenesis,” Frontiers in Neurology 11 (2020): 1028, https://doi.org/10.3389/FNEUR.2020.01028/BIBTEX.
I. Parenti, L. G. Rabaneda, H. Schoen, and G. Novarino, “Neurodevelopmental Disorders: from Genetics to Functional Pathways,” Trends in Neurosciences 43, no. 8 (2020): 608–621, https://doi.org/10.1016/J.TINS.2020.05.004.
L. H. Nguyen and A. Bordey, “Convergent and Divergent Mechanisms of Epileptogenesis in mTORopathies,” Frontiers in Neuroanatomy 15 (2021), https://doi.org/10.3389/FNANA.2021.664695.
C. Bagni and R. S. Zukin, “A Synaptic Perspective of Fragile X Syndrome and Autism Spectrum Disorders,” Neuron 101, no. 6 (2019): 1070–1088, https://doi.org/10.1016/j.neuron.2019.02.041.
M. K. Tripathi, S. K. Ojha, M. Kartawy, et al., “The NO Answer for Autism Spectrum Disorder,” Advanced Science 10 (2023): 2205783, https://doi.org/10.1002/advs.202205783.
B. Fischer-Zirnsak, L. Segebrecht, M. Schubach, et al., “Haploinsufficiency of the Notch Ligand DLL1 Causes Variable Neurodevelopmental Disorders,” The American Journal of Human Genetics 105, no. 3 (2019): 631–639, https://doi.org/10.1016/J.AJHG.2019.07.002.
Y. H. Zhang, T. Wang, Y. F. Li, Y. N. Deng, and F. G. Shen, “Roles of the Notch Signaling Pathway and Microglia in Autism,” Behavioural Brain Research 437 (2023): 114131, https://doi.org/10.1016/J.BBR.2022.114131.
F. Majolo, D. R. Marinowic, and D. C. Machado, “Notch Signaling in human iPS-Derived Neuronal Progenitor Lines from Focal Cortical Dysplasia Patients,” International Journal of Developmental Neuroscience 69, no. 1 (2018): 112–118, https://doi.org/10.1016/J.IJDEVNEU.2018.07.006.
H. Li, X. Wang, C. Hu, et al., “JUN and PDGFRA as Crucial Candidate Genes for Childhood Autism Spectrum Disorder,” Frontiers in Neuroinformatics 16 (2022): 800079, https://doi.org/10.3389/fninf.2022.800079.
M. Kajizuka, T. Miyachi, H. Matsuzaki, et al., “Serum Levels of Platelet-derived Growth Factor BB Homodimers Are Increased in Male Children with Autism,” Progress in Neuro-Psychopharmacology and Biological Psychiatry 34, no. 1 (2010): 154–158, https://doi.org/10.1016/J.PNPBP.2009.10.017.
A. Masi, E. J. Breen, G. A. Alvares, et al., “Cytokine Levels and Associations with Symptom Severity in Male and Female Children with Autism Spectrum Disorder,” Molecular Autism 8, no. 1 (2017): 1–11, https://doi.org/10.1186/S13229-017-0176-2/FIGURES/1.
R. M. Busch, S. Srivastava, O. Hogue, et al., “Neurobehavioral Phenotype of Autism Spectrum Disorder Associated with Germline Heterozygous Mutations in PTEN,” Translational Psychiatry 9, no. 1 (2019): 253, https://doi.org/10.1038/s41398-019-0588-1.
A. Sharma and S. Mehan, “Targeting PI3K-AKT/mTOR Signaling in the Prevention of Autism,” Neurochemistry International 147 (2021): 105067, https://doi.org/10.1016/j.neuint.2021.105067.
S. Fu, L. A. D. Bury, J. Eum, and A. Wynshaw-Boris, “Autism-specific PTEN p.Ile135Leu Variant and an Autism Genetic Background Combine to Dysregulate Cortical Neurogenesis,” The American Journal of Human Genetics 110, no. 5 (2023): 826–845, https://doi.org/10.1016/j.ajhg.2023.03.015.
P. D. Skelton, R. V. Stan, and B. W. Luikart, “The Role of PTEN in Neurodevelopment,” Complex Psychiatry 5, no. 1 (2019): 60–71, https://doi.org/10.1159/000504782.
L. Stertz, J. Di Re, G. Pei, et al., “Convergent Genomic and Pharmacological Evidence of PI3K/GSK3 Signaling Alterations in Neurons from Schizophrenia Patients,” Neuropsychopharmacology 46, no. 3 (2020): 673–682, https://doi.org/10.1038/s41386-020-00924-0.
M. A. Bemben, Q. A. Nguyen, T. Wang, Y. Li, R. A. Nicoll, and K. W. Roche, “Autism-associated Mutation Inhibits Protein Kinase C-mediated Neuroligin-4X Enhancement of Excitatory Synapses,” Proceedings of the National Academy of Sciences 112, no. 8 (2015): 2551–2556, https://doi.org/10.1073/pnas.1500501112.
Q. W. Wu and J. P. Kapfhammer, “The Emerging Key Role of the mGluR1-PKCγ Signaling Pathway in the Pathogenesis of Spinocerebellar Ataxias: a Neurodevelopmental Viewpoint,” International Journal of Molecular Sciences 23, no. 16 (2022): 9169, https://doi.org/10.3390/ijms23169169.
A. Saxena, G. Scaini, D. V. Bavaresco, et al., “Role of Protein Kinase C in Bipolar Disorder: A Review of the Current Literature,” Complex Psychiatry 3, no. 2 (2017): 108–124, https://doi.org/10.1159/000480349.
S. G. Lago, J. Tomasik, G. F. van Rees, et al., “Drug Discovery for Psychiatric Disorders Using High-content Single-cell Screening of Signaling Network Responses Ex Vivo,” Science Advances 5, no. 5 (2019), https://doi.org/10.1126/sciadv.aau9093.
H. Y. Kim, P. G. Suh, and J. I. Kim, “The Role of Phospholipase C in GABAergic Inhibition and Its Relevance to Epilepsy,” International Journal of Molecular Sciences 22, no. 6 (2021): 3149, https://doi.org/10.3390/ijms22063149.
V. Zamboni, R. Jones, A. Umbach, et al., “Rho GTPases in Intellectual Disability: From Genetics to Therapeutic Opportunities,” International Journal of Molecular Sciences 19, no. 6 (2018): 1821, https://doi.org/10.3390/ijms19061821.
M. Anijs, P. Devanna, and S. C. Vernes, “ARHGEF39, a Gene Implicated in Developmental Language Disorder, Activates RHOA and Is Involved in Cell De-Adhesion and Neural Progenitor Cell Proliferation39, a Gene Implicated in Developmental Language Disorder, Activates RHOA and Is Involved in Cell De-Adhesion and Neural Progenitor Cell Proliferation,” Frontiers in Molecular Neuroscience 15 (2022): 39, https://doi.org/10.3389/fnmol.2022.941494.
L.-E. Pillet, N. Cresto, Y. Saillour, et al., “The Intellectual Disability Protein Oligophrenin-1 Controls Astrocyte Morphology and Migration,” Glia 68, no. 9 (2020): 1729–1742, https://doi.org/10.1002/glia.23801.
E. Bloch-Gallego and D. I. Anderson, “Key Role of Rho GTPases in Motor Disorders Associated with Neurodevelopmental Pathologies,” Molecular Psychiatry 28, no. 1 (2023): 118–126, https://doi.org/10.1038/s41380-022-01702-8.
B. Kim, Y. Koh, H. Do, et al., “Aberrant Cortical Layer Development of Brain Organoids Derived from Noonan Syndrome-iPSCs,” International Journal of Molecular Sciences 23, no. 22 (2022): 13861, https://doi.org/10.3390/ijms232213861.
H. S. Zhou and T. B. Chen, “An Integrated Analysis of Hypoxic–ischemic Encephalopathy-Related Cell Sequencing Outcomes via Genes Network Construction,” Ibrain 8, no. 1 (2022): 78–92, https://doi.org/10.1002/IBRA.12025.
C. Miranda-Lourenço, L. Ribeiro-Rodrigues, J. Fonseca-Gomes, et al., “Challenges of BDNF-based Therapies: From Common to Rare Diseases,” Pharmacological Research 162 (2020): 105281, https://doi.org/10.1016/j.phrs.2020.105281.
R. Nieto, M. Kukuljan, and H. Silva, “BDNF and Schizophrenia: From Neurodevelopment to Neuronal Plasticity, Learning, and Memory,” Frontiers in Psychiatry 4 (2013): 42199, https://doi.org/10.3389/fpsyt.2013.00045.
V. Reinhart, S. E. Bove, D. Volfson, D. A. Lewis, R. J. Kleiman, and T. A. Lanz, “Evaluation of TrkB and BDNF Transcripts in Prefrontal Cortex, Hippocampus, and Striatum from Subjects with Schizophrenia, Bipolar Disorder, and Major Depressive Disorder,” Neurobiology of Disease 77 (2015): 220–227, https://doi.org/10.1016/j.nbd.2015.03.011.
T. Ishima, S. Illes, Y. Iwayama, et al., “Abnormal Gene Expression of BDNF, but Not BDNF-AS, in iPSC, Neural Stem Cells and Postmortem Brain Samples from Bipolar Disorder,” Journal of Affective Disorders 290 (2021): 61–64, https://doi.org/10.1016/j.jad.2021.04.042.
S. Kumar, K. Reynolds, Y. Ji, R. Gu, S. Rai, and C. J. Zhou, “Impaired Neurodevelopmental Pathways in Autism Spectrum Disorder: A Review of Signaling Mechanisms and Crosstalk,” Journal of Neurodevelopmental Disorders 11, no. 1 (2019): 1–14, https://doi.org/10.1186/s11689-019-9268-y.
C. C. Jiang, L. S. Lin, S. Long, et al., “Signalling Pathways in Autism Spectrum Disorder: Mechanisms and Therapeutic Implications,” Signal Transduct Target Ther 7, no. 1 (2022): 1–36, https://doi.org/10.1038/s41392-022-01081-0.
C. Song and K. Broadie, “Dysregulation of BMP, Wnt, and Insulin Signaling in Fragile X Syndrome,” Frontiers in Cell and Developmental Biology 10 (2022): 1324, https://doi.org/10.3389/FCELL.2022.934662/BIBTEX.
C. W. Dunnett and A. C. Tamhane, “Step-Down Multiple Tests for Comparing Treatments with a Control in Unbalanced One-Way Layouts,” Statistics in Medicine 10, no. 6 (1991): 939–947, https://doi.org/10.1002/SIM.4780100614.
